Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead'

Published 30/03/2023, 20:01
© Reuters. Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead'
VSTM
-

Benzinga -

  • Mizuho initiated coverage on Verastem Inc (NASDAQ: VSTM) with a Neutral rating and a price target of $2.
  • The analyst says it sees strong clinical rationale, but valuation expansion rests on the go-forward strategy in - Low-Grade Serous Ovarian Cancer (LGSOC) and clinical signals from the KRAS G12C programs.
  • The analyst writes that the shares are underpriced relative to the LGSOC market (~$1.5 billion) but waiting for clarity on accelerated approval and confirmatory trial, which could be a catalyst for valuation expansion.
  • Mizuho writes that VSTM shares are trading below what can be seen as the opportunity in LGSOC based on a multiple of peak revenue (less $100 million market cap versus peak revenue forecast of ~$800 million).
  • The analyst writes that the RAMP-201 interim data confirmed that the activity of avutometinib + defactinib looks competitive with other MEK inhibitors used in the setting.
  • Mizuho also writes that KRAS G12C combination programs offer upside as the market potential could be up to 2-3X LGSOC, but awaiting data - 2H23.
  • Price Action: VSTM shares are down 9.92% at $0.41 on the last check Thursday.
Mar 2022Truist SecuritiesInitiates Coverage OnBuy
Jul 2021HC Wainwright & Co.MaintainsBuy
Jul 2021Alliance Global PartnersInitiates Coverage OnBuy

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.